-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Trevi Therapeutics, Maintains $19 Price Target

Benzinga·01/08/2026 13:04:08
語音播報
D. Boral Capital analyst Jason Kolbert maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $19 price target.